Olema Pharmaceuticals (NASDAQ:OLMA) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Olema Pharmaceuticals (NASDAQ:OLMA) in a research note issued to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $30.00 price objective on the stock. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q1 2025 earnings at ($0.59) EPS, Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.03) EPS, FY2026 earnings at ($3.86) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($3.10) EPS and FY2029 earnings at ($2.41) EPS.

Olema Pharmaceuticals Stock Up 2.7 %

NASDAQ:OLMA opened at $4.23 on Wednesday. The company has a market cap of $242.37 million, a P/E ratio of -1.93 and a beta of 2.11. The firm’s 50 day moving average is $5.09 and its two-hundred day moving average is $8.35. Olema Pharmaceuticals has a fifty-two week low of $3.94 and a fifty-two week high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.12. Research analysts forecast that Olema Pharmaceuticals will post -2.33 earnings per share for the current fiscal year.

Insider Activity

In other Olema Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv acquired 300,000 shares of the company’s stock in a transaction dated Wednesday, January 8th. The stock was bought at an average price of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the transaction, the insider now directly owns 7,800,000 shares of the company’s stock, valued at approximately $44,928,000. The trade was a 4.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 19.40% of the company’s stock.

Institutional Trading of Olema Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in OLMA. Bain Capital Life Sciences Investors LLC purchased a new position in Olema Pharmaceuticals in the fourth quarter valued at about $43,551,000. Paradigm Biocapital Advisors LP grew its stake in shares of Olema Pharmaceuticals by 32.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,304,970 shares of the company’s stock valued at $42,588,000 after buying an additional 1,801,370 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Olema Pharmaceuticals by 14.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 3,687,374 shares of the company’s stock valued at $44,027,000 after buying an additional 475,447 shares during the period. MPM Bioimpact LLC lifted its position in Olema Pharmaceuticals by 8.7% during the 4th quarter. MPM Bioimpact LLC now owns 2,912,550 shares of the company’s stock worth $16,980,000 after acquiring an additional 231,954 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Olema Pharmaceuticals by 6.0% in the 4th quarter. Vanguard Group Inc. now owns 2,685,009 shares of the company’s stock worth $15,654,000 after acquiring an additional 152,117 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.